GENECODE is a private Estonian-American-Finnish-Dutch R&D company, developing novel disease modifying drugs. Our overall ambition is to develop neuroprotective and potentially neurorestorative treatment which is –as yet- unavailable. With respect to anti-viral strategies, GeneCode designed and develops improved molecules using antisense mechanism of action which targets viral genomes and transcripts. Our scientific partners are all internationally well known leading scientists.